Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

被引:54
作者
Lalezari, Jacob P. [1 ]
Latiff, Gulam H. [2 ]
Brinson, Cynthia [3 ]
Echevarria, Juan [4 ]
Trevino-Perez, Sandra [5 ]
Bogner, Johannes R. [6 ]
Thompson, Melanie [7 ]
Fourie, Jan [8 ]
Sussmann Pena, Otto A. [9 ]
Mendo Urbina, Fernando C. [10 ]
Martins, Marcelo [11 ]
Diaconescu, Iulian G. [12 ]
Stock, David A. [13 ]
Joshi, Samit R. [13 ]
Hanna, George J. [14 ]
Lataillade, Max [13 ]
机构
[1] Quest Clin Res, San Francisco, CA 94115 USA
[2] Maxwell Ctr, Durban, South Africa
[3] Cent Texas Clin Res, Austin, TX USA
[4] Hosp Nacl Cayetano Heredia, Dept Trop Infect Dis & Dermatol, Lima, Peru
[5] Mexico Ctr Clin Res, Mexico City, DF, Mexico
[6] Hosp Univ Munich, Sect Clin Infect Dis Med 4, Munich, Germany
[7] AIDS Res Consortium Atlanta, Atlanta, GA USA
[8] Dr J Fourie Med Ctr, Dundee, Scotland
[9] Asistencia Cient Alta Complejidad SAS, Bogota, Colombia
[10] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[11] Inst Oulton, Cordoba, Argentina
[12] Univ Med & Pharm, Craiova, Romania
[13] Bristol Myers Squibb Co, Res & Dev, Wallingford, CT 06492 USA
[14] Bristol Myers Squibb Co, Res & Dev, Princeton, NJ USA
来源
LANCET HIV | 2015年 / 2卷 / 10期
关键词
CLASS VIROLOGICAL FAILURE; ANTIRETROVIRAL THERAPY; ACTIVE COMPONENT; BMS-626529; MONOTHERAPY;
D O I
10.1016/S2352-3018(15)00177-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background BMS-663068 is an oral prodrug of BMS-626529, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 cells. AI438011 is an ongoing trial investigating the efficacy, safety, and dose-response of BMS-663068 in treatment-experienced, HIV-1-infected patients. Herein we present the results of the primary analysis. Methods AI438011 is a phase 2b, randomised, active-controlled trial, at 53 hospitals and outpatient clinics across ten countries in North and South America, Europe, and Africa. Individuals with an HIV-1 RNA viral load of at least 1000 copies per mL and a BMS-626529 half-maximum inhibitory concentration lower than 100 nmol/L were randomly assigned (1:1:1:1:1) to receive either BMS-663068 at 400 mg twice daily, 800 mg twice daily, 600 mg once daily, or 1200 mg once daily or ritonavir-boosted atazanavir (300 mg of atazanavir and 100 mg of ritonavir once daily), each with 400 mg of raltegravir twice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone. The sponsor, participants, and investigators were masked for BMS-663068 dose but not for allocation. Primary endpoints were the proportion of patients with an HIV-1 RNA viral load less than 50 copies per mL (response rate) at week 24 and the frequency of serious adverse events and adverse events leading to discontinuation, up to the week 24 analysis. The primary analyses included all patients who received at least one dose of study drug (modified intention-to-treat population). This study is registered at ClinicalTrials.gov, NCT01384734. Findings Between July 26, 2011, and July 16, 2012, 581 participants were assessed for eligibility. Of these, 254 patients were randomly assigned to receive either BMS-663068 (n=52 for the 400 mg twice daily group, n=50 for the 800 mg twice daily group, n=51 for the 600 mg once daily group, and n=50 for the 1200 mg once daily group) or ritonavir-boosted atazanavir (n=51). 200 patients received at least one dose of BMS-663068, and 51 patients received at least one dose of ritonavir-boosted atazanavir. At week 24, 40 (80%) of 50 patients in the BMS-663068 400 mg twice daily group, 34 (69%) of 49 patients in the 800 mg twice daily group, 39 (76%) of 51 patients in the 600 mg once daily group, and 36 (72%) of 50 patients in the 1200 mg once daily group had an HIV-1 RNA viral load less than 50 copies per mL, compared with 38 (75%) of 51 patients in the ritonavir-boosted atazanavir group. Serious adverse events were noted in 13 (7%) of 200 patients in the BMS-663068 groups and five (10%) of the 51 patients in the ritonavir-boosted atazanavir group. Four (2%) of the 200 patients in the BMS-663068 groups and two (4%) of the 51 patients in the ritonavir-boosted atazanavir group discontinued because of adverse events. No serious adverse events or adverse events leading to discontinuation were BMS-663068-related. Grade 2-4 adverse events related to study drug(s) occurred in 17 (9%) of 200 patients across the BMS-663068 groups and 14 (27%) of 51 patients in the ritonavir-boosted atazanavir group. For the BMS-663068 groups these events were mostly single instances with no dose relation and for the ritonavir-boosted atazanavir group these were mostly gastrointestinal or hepatobiliary disorders associated with hyperbilirubinaemia. Interpretation In a comparison with ritonavir-boosted atazanavir, efficacy and safety of BMS-663068 up to the week 24 analysis support continued development of BMS-663068, which is being assessed in a phase 3 trial in heavily treatment-experienced individuals.
引用
收藏
页码:E427 / E437
页数:11
相关论文
共 20 条
  • [1] Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009
    Abgrall, S.
    Ingle, S. M.
    May, M. T.
    Cornish, R.
    Costagliola, D.
    Mercie, P.
    Cavassini, M.
    Reekie, J.
    Samji, H.
    Gill, M. J.
    Crane, H. M.
    Tate, J.
    Sterling, T. R.
    Antinori, A.
    Reiss, P.
    Saag, M. S.
    Mugavero, M. J.
    Phillips, A.
    Manzardo, C.
    Wasmuth, J. C.
    Stephan, C.
    Guest, J. L.
    Sirvent, J. L. G.
    Sterne, J. A. C.
    [J]. AIDS, 2013, 27 (05) : 803 - 813
  • [2] [Anonymous], GUID US ANT AG HIV 1
  • [3] Bristol-Myers Squibb, 2013, REY PRESCR INF
  • [4] Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug
    Brown, Jonathan
    Chien, Caly
    Timmins, Peter
    Dennis, Andrew
    Doll, Walter
    Sandefer, Erik
    Page, Richard
    Nettles, Richard E.
    Zhu, Li
    Grasela, Dennis
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (06) : 1742 - 1751
  • [5] Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008
    Elzi, Luigia
    Marzolini, Catia
    Furrer, Hansjakob
    Ledergerber, Bruno
    Cavassini, Matthias
    Hirschel, Bernard
    Vernazza, Pietro
    Bernasconi, Enos
    Weber, Rainer
    Battegay, Manuel
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (01) : 57 - 65
  • [6] European AIDS Clinical Society, 2014, EUR AIDS CLIN SOC GU
  • [7] Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Fätkenheuer, G
    Pozniak, AL
    Johnson, MA
    Plettenberg, A
    Staszewski, S
    Hoepelman, AIM
    Saag, MS
    Goebel, FD
    Rockstroh, JK
    Dezube, BJ
    Jenkins, TM
    Medhurst, C
    Sullivan, JF
    Ridgway, C
    Abel, S
    James, IT
    Youle, M
    van der Ryst, E
    [J]. NATURE MEDICINE, 2005, 11 (11) : 1170 - 1172
  • [8] Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action
    Langley, David R.
    Kimura, S. Roy
    Sivaprakasam, Prasanna
    Zhou, Nannan
    Dicker, Ira
    McAuliffe, Brian
    Wang, Tao
    Kadow, John F.
    Meanwell, Nicholas A.
    Krystal, Mark
    [J]. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2015, 83 (02) : 331 - 350
  • [9] Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up
    Lee, Frederick J.
    Amin, Janaki
    Carr, Andrew
    [J]. PLOS ONE, 2014, 9 (05):
  • [10] Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors
    Li, Zhufang
    Zhou, Nannan
    Sun, Yongnian
    Ray, Neelanjana
    Lataillade, Max
    Hanna, George J.
    Krystal, Mark
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (09) : 4172 - 4180